KL
NPCE icon

KCK Ltd’s Neuropace NPCE Stock Holding History

KCK Ltd’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,270,845
Closed -$59M – 3
2024
Q4 		$59M Buy
+5,270,845
New +$45.8M 78.69% 1
2023
Q3 		$54.7M Hold
5,621,111
– – 77.7% 1
2023
Q2 		$25.2M Hold
5,621,111
– – 39.57% 2
2023
Q1 		$26.1M Hold
5,621,111
– – 38.74% 2
2022
Q4 		$8.38M Hold
5,621,111
– – 12.55% 2
2022
Q3 		$21.1M Hold
5,621,111
– – 40.88% 2
2022
Q2 		$27.8M Hold
5,621,111
– – 39.09% 2
2022
Q1 		$46.1M Hold
5,621,111
– – 45.03% 2
2021
Q4 		$56.7M Buy
+5,621,111
New +$73M 40.01% 2

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCK Ltd's NPCE Position: Q1 2025 in Review

KCK Ltd sold out of Neuropace (NPCE) in Q1 2025, closing a stake of 5,270,845 shares — an estimated $59M sold.

KCK Ltd first reported a position in NPCE in Q4 2021 and held it in 9 quarters. The position peaked at $59M in Q4 2024. 90 funds tracked by Wall St. Rank hold NPCE as of Q1 2025.

  • KCK Ltd reported no remaining Neuropace position as of Q1 2025 after selling out during the quarter.
  • KCK Ltd sold 5,270,845 Neuropace shares in Q1 2025, an estimated $59M.
  • KCK Ltd first reported a position in Neuropace in Q4 2021 and held it in 9 quarters.
  • KCK Ltd's Neuropace position peaked at $59M in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Neuropace as of Q1 2025.

Based on KCK Ltd's 13F filing for Q1 2025, filed 11 Jul 2025.